Related Experiment Video
Updated: Apr 28, 2026
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
11.3K
A study to evaluate the use of extended release divalproex
Michael M Stone1, Robert M A Hirschfeld
1Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, TX, USA.
International Journal of Psychiatry in Clinical Practice
|June 19, 2014
Summary
Extended release divalproex demonstrated good tolerability and efficacy in psychiatric outpatients. This review suggests the new formulation is a viable option for managing psychiatric conditions.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Pharmacy
Background:
- Delayed release divalproex is a standard treatment for psychiatric conditions.
- An extended release (ER) formulation of divalproex with altered pharmacokinetics is available.
- The efficacy of ER divalproex in psychiatric patients requires further investigation.
Purpose of the Study:
- To evaluate the efficacy and tolerability of extended release divalproex.
- To assess the safety profile of ER divalproex in psychiatric outpatients.
Main Methods:
- A retrospective chart review was conducted.
- Fourteen psychiatric outpatients treated with ER divalproex were analyzed over a 10-month period.
- Data on efficacy, tolerability, and side effects were collected.
Main Results:
- Only one out of 14 patients could not tolerate ER divalproex.
- No patients discontinued the medication due to lack of efficacy or safety concerns.
- Minor side effects were reported in patients who continued ER divalproex treatment.
Conclusions:
- Extended release divalproex appears to be well-tolerated and effective in psychiatric outpatients.
- The findings suggest ER divalproex is a promising treatment option.
- Further research is necessary to confirm these preliminary results.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
297
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
297
01:19Modified-Release Drug Delivery Systems: Overview
231
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
231
01:20Antiepileptic Drugs: Potassium Channel Activators
1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
1.0K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
253
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
253
01:19Depolarizing Blockers: Pharmocokinetics
776
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
776